Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Revance Therapeutics, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Revance Therapeutics, Inc. (“Revance” or the “Company”) (NasdaqGM: RVNC) of the possibility to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.
A complaint has been filed against Revance in United States District Court for the Northern District of California. It alleges that Revance had not commenced a Phase 3 clinical trial of RT0001—its lead product under development for the treatment of wrinkles around the eyes—in the first quarter of 2014 as it had announced in its June 19, 2014 follow-on public stock offering (the “Offering”).
Further, the complaint accuses the Company of possessing neither the quantity nor the quality of RT001 required to complete a Phase 3 clinical trial under FDA guidelines.
After correspondence between the FDA and the Company revealing this news was made public, Revance’s stock price dropped to as low as 50% of the $30. 50 per share Offering price in the following month, damaging investors.
If you invested in Revance stock or options during or around the Offering and would like to discuss your legal rights, please fill out the form below. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to email@example.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding Revance’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.